Q3 2025 Azenta Inc Earnings Call Transcript
Key Points
- Azenta Inc (AZTA) reported a 260 basis point expansion in adjusted EBITDA margin year over year, demonstrating strong execution and cost discipline.
- The company has a robust M&A funnel with high-quality strategic tuck-in opportunities, indicating potential for accelerated revenue growth and profitability.
- Azenta Inc (AZTA) ended the quarter with a strong financial position, holding $550 million in cash and no outstanding debt.
- The company saw growth in next-generation sequencing, sample storage, and product services, highlighting areas of strength within its portfolio.
- Azenta Inc (AZTA) reaffirmed its full-year 2025 guidance of organic revenue growth between 3% to 5% and adjusted EBITDA margin expansion of 300 basis points, showing confidence in its financial outlook.
- Core products revenue experienced weakness due to ongoing funding and investment constraints, impacting overall performance.
- Sample Management Solutions (SMS) revenue declined 4% year over year on a reported basis, primarily due to softer bookings and timing delays in automated stores product lines.
- Gene synthesis revenue declined high single digits year over year, reflecting continued softness among key pharma accounts.
- Sanger sequencing revenue declined mid-teens year over year as the industry transitions towards newer sequencing technologies.
- The company recorded a non-cash loss of $69 million on assets held for sale related to B Medical Systems, impacting financial results.
Greetings, and welcome to the Azenta Q3 2025 financial results. (Operator Instructions) As a reminder, this conference is being recorded Tuesday, August 5, 2025. I will now like turn the conference over to Yvonne Perron, Vice President, FP&A, and Investor Relations. Please go ahead.
Thank you, operator, and good morning to everyone on the line today. We would like to welcome you to our earnings conference call for the third quarter of fiscal year 2025.
Our third-quarter earnings press release was issued before the open of the market today and is available on our Investor Relations website located at investors.azenta.com in addition to the supplementary PowerPoint slides that will be used during the prepared remarks today. Please note that effective the first fiscal quarter of 2025, the results of B Medical Systems are treated as discontinued operations.
I would like to remind everyone that during the course of the call, we will be making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
